RMD Price Prediction Next Week
Technical Analysis Recent price action shows RMD trading in a consolidation pattern between $177-184. The stock has formed higher lows over the past week, indicating building bullish momentum.
News Sentiment & Fundamentals
- Warren Buffett's Patient Investor model gives RMD a strong 92% rating, highlighting predictable profitability and low debt
- Multiple analysts maintain bullish stance:
- Jarden maintains Buy rating with PT A$41.48
- UBS also issued Buy rating
- Only Wilsons downgraded to Hold
- Strong financial performance with Q4 revenue of A$1.28B (+10.3% YoY) and net profit of A$344.62M (+65% YoY)
Price Prediction (Next Week) Based on technical analysis and positive fundamentals:
- Support levels: $177.43, $181.86
- Resistance levels: $184.54, $186.50
- Target price range: $184-188
Trading Recommendation BUY with entry at current levels ($182.79):
- Short-term target: $186.50 (+2%)
- Stop loss: $177.43 (-2.9%)
- Risk/Reward ratio: 0.69
Rationale:
- Positive momentum indicators
- Strong fundamental backdrop
- Multiple analyst buy ratings
- Clear technical support levels
RMD Similar Chart Price Prediction
The price of RMD is predicted to go up 4.5%, based on the high correlation periods with MBIN. The similarity of these two price pattern on the periods is 94.85%.
RMD
MBIN
Up: 4.5%Similarity: 94.85%
RMD Revenue Forecast
RMD EPS Forecast
RMD FAQs
What is bull’s view on RMD?
What is bear's view on RMD?
What is RMD revenue forecast for next quarter？
What is RMD eps forecast for next quarter？
RMD VS S&P500
The long-term growth opportunity for respiratory homecare devices is sizable as both developed and emerging markets are still significantly underpenetrated.
The focus on cloud-connected devices has led to increased adherence, supporting both reimbursement rates and the resupply of masks and accessories.
ResMed stands to benefit from Philips' significant product recall and the launch of its new flagship product, AirSense 11.
RMD Analyst's Forecast
Brett Fishbin
Keybanc
Buy
2025-01-31
Price Target
$266 → $280
Upside
+18.55%
KeyBanc raised the firm's price target on ResMed to $280 from $266 on higher estimates and multiple, while keeping an Overweight rating on the shares. The firm believes Q2 trends were supportive of recent stock performance and sees continued upside based on its current momentum.
Adam Maeder
Piper Sandler
Hold
2025-01-31
Price Target
$252 → $260
Upside
+10.09%
Adam Maeder
Piper Sandler
Hold
2025-01-10
Price Target
$252
Upside
+7.78%
